Last reviewed · How we verify

ACEI, SGLT-2i

Mansoura University · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

ACEI, SGLT-2i is a Small molecule drug developed by Mansoura University. It is currently FDA-approved. Also known as: Captopril, forxiga.

ACE inhibitors and SGLT-2 inhibitors are used to treat conditions such as Diabetes Mellitus, Cardiovascular Diseases, and Heart Failure of Reduced Ejection Fraction (HFrEF). They are also studied in combination with other treatments, including beta blockers, for these conditions.

At a glance

Generic nameACEI, SGLT-2i
Also known asCaptopril, forxiga
SponsorMansoura University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ACEI, SGLT-2i

What is ACEI, SGLT-2i?

ACEI, SGLT-2i is a Small molecule drug developed by Mansoura University.

Who makes ACEI, SGLT-2i?

ACEI, SGLT-2i is developed and marketed by Mansoura University (see full Mansoura University pipeline at /company/mansoura-university).

Is ACEI, SGLT-2i also known as anything else?

ACEI, SGLT-2i is also known as Captopril, forxiga.

What development phase is ACEI, SGLT-2i in?

ACEI, SGLT-2i is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing